Clinical trial · Observational
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
"DEMOS" - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
NCT07256015CI-TRIAL-00098108recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Psoriasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Deucravacitinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Participants with moderate/severe psoriasis receiving deucravacitinib
- interventionNames
- Drug: Deucravacitinib
Primary outcomes (2)
- measure
- The percentage of participants still receiving deucravacitinib treatment
- timeFrame
- Week 24 and 52
- measure
- Absolute Psoriasis Area and Severity Index (PASI)
- timeFrame
- Baseline and Weeks 16, 24 and 52
Secondary outcomes (18)
- measure
- Participant age in years
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA) * Patients have moderate to severe plaque psoriasis * Patients have signed informed consent form (ICF) Exclusion Criteria: * Simultaneous participation in any interventional study for their moderate-to-severe psoriasis * Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF
References
Publications (0)
Data not yet available
No reference posted for this study.